Vacuolin-1 inhibits endosomal trafficking and metastasis via CapZβ

Area of Science:

• Oncology
• Cell Biology
• Pharmacology

Background:

• Metastasis is a primary driver of cancer mortality, with limited therapeutic options.
• Endosomal trafficking pathways are crucial in tumor metastasis.
• Vacuolin-1 (V1) is a chemical inhibitor of autophagosome-lysosome fusion and endosomal-lysosomal degradation.

Purpose of the Study:

• To evaluate the anti-metastatic potential of vacuolin-1 (V1) in vitro and in vivo.
• To elucidate the molecular mechanisms underlying V1's anti-metastatic effects.

Main Methods:

• In vitro assays assessing colony formation, migration, and invasion of cancer cells.
• In vivo studies using mouse models of breast cancer and melanoma.
• Identification of V1 binding proteins using biochemical approaches.

Main Results:

• V1 significantly inhibited cancer cell colony formation, migration, and invasion.
• V1 disrupted focal adhesion dynamics by inhibiting integrin recycling and degradation.
• V1 suppressed tumor growth and metastasis in experimental mouse models.
• Capping protein Zβ (CapZβ) was identified as a V1 binding protein essential for V1's anti-metastatic activity.

Conclusions:

• V1 demonstrates significant anti-metastatic activity in preclinical models.
• V1 targets CapZβ to inhibit endosomal trafficking, thereby suppressing cancer cell migration and metastasis.
• V1 represents a potential therapeutic agent for combating cancer metastasis.